Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients

Clinica Chimica Acta

Volumn 452, Issue , 2016, Pages 109-119

  Lu, Hongbiao ^a,b,c   Busch, Jonas ^a   Jung, Monika ^a   Rabenhorst, Silke ^a   Ralla, Bernhard ^a   Kilic, Ergin ^a   Mergemeier, Steffen ^d   Budach, Nils ^a   Fendler, Annika ^a,b,e   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d CONGEN Biotechnologie GmbH ^*  (Germany)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Circulating cell free DNA; Clear cell renal cell carcinoma; Diagnostic; Metastasis; Predictive models; Prognostic markers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN 1; AMYLOID PRECURSOR PROTEIN 2; AMYLOID PRECURSOR PROTEIN 3; CIRCULATING CELL FREE DNA; DNA FRAGMENT; EDETIC ACID; MITO 1 PROTEIN; MITO 2 PROTEIN; MITOCHONDRIAL DNA; SINE 1 PROTEIN; SINE 2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALU SEQUENCE; APP 1 GENE; APP 2 GENE; APP 3 GENE; APP GENE; ARTICLE; BASE PAIRING; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC KIT; DNA EXTRACTION; DNA FRAGMENTATION; FEMALE; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; NEPHRECTOMY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; REGRESSION ANALYSIS; SINE 1 GENE; SINE 2 GENE; TUMOR RECURRENCE; VALIDITY; BLOOD; CARCINOMA, RENAL CELL; CELL NUCLEUS; GENETICS; KIDNEY NEOPLASMS; MIDDLE AGED; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

AGED; CARCINOMA, RENAL CELL; CELL NUCLEUS; DNA, MITOCHONDRIAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS;

EID: 84946779822     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.11.009     Document Type: Article

References (42)

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136:E359-E386.
2. Gupta K., Miller J.D., Li J.Z., Russell M.W., Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 2008, 34:193-205.
3. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N. Engl. J. Med. 2005, 353:2477-2490.
4. Sun M., Shariat S.F., Cheng C., Ficarra V., Murai M., Oudard S., et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur. Urol. 2011, 60:644-661.
5. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim. Biophys. Acta 1775, 2007:181-232.
6. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
7. Giacona M.B., Ruben G.C., Iczkowski K.A., Roos T.B., Porter D.M., Sorenson G.D. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998, 17:89-97.
8. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.
9. Wang B.G., Huang H.Y., Chen Y.C., Bristow R.E., Kassauei K., Cheng C.C., et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003, 63:3966-3968.
10. Jung K., Fleischhacker M., Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin. Chim. Acta 2010, 411:1611-1624.
11. Hauser S., Zahalka T., Ellinger J., Fechner G., Heukamp L.C., von R.A., et al. Cell-free circulating DNA: diagnostic value in patients with renal cell cancer. Anticancer Res. 2010, 30:2785-2789.
12. de Martino M., Klatte T., Haitel A., Marberger M. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 2012, 118:82-90.
13. Feng G., Ye X., Fang F., Pu C., Huang H., Li G. Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Dis. Markers 2013, 34:105-111.
14. Wan J., Zhu L., Jiang Z., Cheng K. Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma. Urol. Int. 2013, 91:273-278.
15. El Messaoudi S., Rolet F., Mouliere F., Thierry A.R. Circulating cell free DNA: preanalytical considerations. Clin. Chim. Acta 2013, 424:222-230.
16. Ellinger J., Muller D.C., Muller S.C., Hauser S., Heukamp L.C., von R.A., et al. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol. Oncol. 2012, 30:509-515.
17. Yu M. Circulating cell-free mitochondrial DNA as a novel cancer biomarker: opportunities and challenges. Mitochondrial DNA 2012, 23:329-332.
18. Mouliere F., Thierry A.R. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert. Opin. Biol. Ther. 2012, 12(Suppl. 1):S209-S215.
19. Gorges T.M., Schiller J., Schmitz A., Schuetzmann D., Schatz C., Zollner T.M., et al. Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA. Biomarkers 2012, 17:498-506.
20. Nicklas J.A., Noreault-Conti T., Buel E. Development of a real-time method to detect DNA degradation in forensic samples. J. Forensic Sci. 2012, 57:466-471.
21. Batzer M.A., Deininger P.L. Alu repeats and human genomic diversity. Nat. Rev. Genet. 2002, 3:370-379.
22. Altman D.G., McShane L.M., Sauerbrei W., Taube S.E. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 2012, 9.
23. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin. Chem. 2003, 49:1-6.
24. Swinkels D.W., Wiegerinck E., Steegers E.A.P., de Kok J.B. Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin. Chem. 2003, 49:525-526.
25. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55:611-622.
26. Pinzani P., Salvianti F., Zaccara S., Massi D., De G.V., Pazzagli M., et al. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin. Chim. Acta 2011, 412:2141-2145.
27. Vickers A.J., Elkin E.B. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Mak. 2006, 26:565-574.
28. Stephan C., Jung K., Semjonow A., Schulze-Forster K., Cammann H., Hu X., et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin. Chem. 2013, 59:280-288.
29. Harrell F.E. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis 2001, Springer, New York.
30. Faul F., Erdfelder E., Buchner A., Lang A.G. Statistical power analyses using G Power 3.1: tests for correlation and regression analyses. Behav. Res. Methods 2009, 41:1149-1160.
31. Ralla B., Stephan C., Meller S., Dietrich D., Kristiansen G., Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit. Rev. Clin. Lab. Sci. 2014, 51:200-231.
32. Page K., Guttery D.S., Zahra N., Primrose L., Elshaw S.R., Pringle J.H., et al. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One 2013, 8.
33. Malentacchi F., Pizzamiglio S., Verderio P., Pazzagli M., Orlando C., Ciniselli C.M., et al. Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience. Clin. Chem. Lab. Med. 2015, (Epub ahead of print). 10.1515/cclm-2014-1161.
34. The Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
35. Altimari A., Grigioni A.D., Benedettini E., Gabusi E., Schiavina R., Martinelli A., et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am. J. Clin. Pathol. 2008, 129:756-762.
36. Kohler C., Radpour R., Barekati Z., Asadollahi R., Bitzer J., Wight E., et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol. Cancer 2009, 8:105.
37. Papadopoulou E., Davilas E., Sotiriou V., Georgakopoulos E., Georgakopoulou S., Koliopanos A., et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. N. Y. Acad. Sci. 2006, 1075:235-243.
38. Sozzi G., Conte D., Leon M., Ciricione R., Roz L., Ratcliffe C., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 2003, 21:3902-3908.
39. Bovelstad H.M., Nygard S., Borgan O. Survival prediction from clinico-genomic models-a comparative study. BMC Bioinformatics 2009, 10:413.
40. Gerszten R.E., Wang T.J. The search for new cardiovascular biomarkers. Nature 2008, 451:949-952.
41. Busch J., Ralla B., Jung M., Wotschofsky Z., Trujillo-Arribas E., Schwabe P., et al. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J. Exp. Clin. Cancer Res. 2015, 34:61.
42. Wotschofsky Z., Busch J., Jung M., Kempkensteffen C., Weikert S., Schaser K.D., et al. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin. Chim. Acta 2013, 416:5-10.